pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 Last week, it licensed a series of fibroblast activation protein (FAP) targeting agents from iTheranostics that can be used to image and potentially to treat tumours. That was acquired from Endocyte in 2018 in a $2.1

DNA 52

DNA Licensing Licensing Gene Therapy 52

The Pharma Data

APRIL 15, 2022

The test is performed by a qualified, trained operator under the supervision of a health care provider licensed or authorized by state law to prescribe tests and can provide results in less than three minutes. director of the FDA’s Center for Devices and Radiological Health. for the next public health emergency.”.

Radiology 52

Radiology Cosmetics Production Licensing 52

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.

Licensing 52

Licensing Licensing Medicine Development 52

pharmaphorum

OCTOBER 4, 2022

On 27th September 2022, the Food and Drug Administration (FDA) issued its final guidance for industry and FDA staff clinical decision support (CDS) software, which has been anticipated since the Center for Devices and Radiological Health (CDRH) listed the guidance as a top priority for fiscal year 2022.

Development 105

Development Regulation Cosmetics Life Science 105

The Pharma Data

MARCH 16, 2021

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020 , the human monoclonal antibodies were optimised by AstraZeneca with half-life extension and reduced Fc receptor binding. The extended agreement is not anticipated to impact the Company’s financial guidance for 2021.

Antibody 52

Antibody Trials Radiology Development 52

The Pharma Data

NOVEMBER 9, 2021

This procurement of molnupiravir will be supported in whole with civil finances from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, in collaboration with the DOD Joint Program Executive Office for Chemical, Biological, Radiological (..)

Medicine 52

Medicine Radiology Development Drugs 52

The Pharma Data

JUNE 25, 2021

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020 , the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein 2 and were optimised by AstraZeneca with half-life extension and reduced Fc receptor binding. W911QY-21-9-0001.

Trials 52

Trials Antibody In-Vitro Medicine 52

pharmaphorum

SEPTEMBER 30, 2022

There will still be much debate about the exact license granted to the drug and cost-effectiveness deliberations, according to Prof Passmore. “It is very likely more people will come to see their doctor now – and we, as doctors, need to be ready.

Clinical Trials 52

Clinical Trials Clinical Trials Sales Drugs 52

The Pharma Data

MARCH 29, 2022

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein16 and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. W911QY-21-9-0001.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

MARCH 25, 2022

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(10) and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. W911QY-21-9-0001.

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

The Pharma Data

OCTOBER 12, 2021

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein1 and were optimised by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. W911QY-21-9-0001.

Trials 52

Trials Development Antibody Radiology 52

The Pharma Data

AUGUST 22, 2021

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(7) and were optimised by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. W911QY-21-9-0001. About AstraZeneca.

Trials 52

Trials Antibody Vaccination Vaccine 52

XTalks

JUNE 12, 2023

Siemens Healthineers further demonstrated its commitment to innovation at the European Congress of Radiology in Vienna, showcasing its revamped Acuson ultrasound portfolio. This acquisition granted BD access to advanced assays licensed from the EuroFlow Consortium, an independent scientific network in hematology and immunology.

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

The Pharma Data

DECEMBER 23, 2020

Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA). It will be funded by the U.S.

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

AUGUST 5, 2021

Earnings were also diminished by a negative product mix, currency effects of 111 million euros, and the later receipt of license revenues. Pharmaceuticals raises sales and earnings. Sales of prescription medicines (Pharmaceuticals) rose by 16.2 percent (Fx & portfolio adj.) to 4.494 billion euros.

Sales 52

Sales Production Gene Therapy Allergies 52

FDA Law Blog

DECEMBER 11, 2023

FDA’s assumption that 50% of the tests will be exempt is particularly baffling because the laboratories are ones licensed to perform high complexity tests. See Jeff Shuren & William Maisel, Looking Ahead to 2022 as FDA’s Center for Devices and Radiological Health Manages a Sustained Increase in Workload , FDA Voices (Dec.

In-Vitro 69

In-Vitro Regulation Production Development 69